Abstract Library

#1777 Tumour Size Is Not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort

Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Mills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A,

Keywords: pNET, surveillance, incidental,

#1112 Second Primary Malignancies in Patients with Neuroendocrine Tumors

Introduction: Numerous studies have demonstrated an elevated incidence of second primary malignancies (SPM) in patients with neuroendocrine tumours (NET).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Clift A, Drymousis P, Al-Nahhas A, Wasan H, Martin J,

Keywords: neuroendocrine, neoplasm, second, cancers,

#965 Metabonomic Profiling: A Novel Approach in Neuroendocrine Neoplasias

Introduction: There is a substantial unmet need for novel biomarkers for neuroendocrine neoplasms (NEN).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Jiminez B

Authors: Jimenez B, Drymousis P, Kinross J, Nicholson J, Frilling A,

Keywords: Metabonomics, NEN,

#961 Heterogeneity in the Ki-67 Index of Neuroendocrine Tumors

Introduction: Tumor heterogeneity due to tumor evolution is becoming more widely recognised. Neuroendocrine tumors (NET) are routinely graded using the Ki-67 index based on a single tumor location, however, this could lead to undergrading if the Ki-67 index is higher at the metastatic site.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Miller H, Flora R, Drymousis P, Wasan H, Goldin R,

Keywords: tumor heterogeneity, Ki-67,

#857 Video Capsule Endoscopy as a Tool to Detect Small Bowel Neuroendocrine Tumors

Introduction: Recent studies suggest that video capsule endoscopy (CE) should be implemented in diagnostic work-up in patients with suspected small bowel tumors. Small bowel is the primary site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the localization of the primary tumors remains obscure.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Martin J, Smith G, Drymousis P, Frilling A,

Keywords: NET, unknown primary, capsule endoscopy,